170 related articles for article (PubMed ID: 22777834)
1. Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.
Bokacheva L; Kotedia K; Reese M; Ricketts SA; Halliday J; Le CH; Koutcher JA; Carlin S
NMR Biomed; 2013 Feb; 26(2):151-63. PubMed ID: 22777834
[TBL] [Abstract][Full Text] [Related]
2.
Grkovski M; Emmas SA; Carlin SD
J Nucl Med; 2017 Oct; 58(10):1567-1573. PubMed ID: 28360207
[TBL] [Abstract][Full Text] [Related]
3. The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Cancer Xenograft Model.
Melsens E; Verberckmoes B; Rosseel N; Vanhove C; Descamps B; Pattyn P; Ceelen W
Eur Surg Res; 2017; 58(3-4):95-108. PubMed ID: 28002822
[TBL] [Abstract][Full Text] [Related]
4. Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate.
Bradley DP; Tessier JJ; Lacey T; Scott M; Jürgensmeier JM; Odedra R; Mills J; Kilburn L; Wedge SR
Magn Reson Imaging; 2009 Apr; 27(3):377-84. PubMed ID: 18814988
[TBL] [Abstract][Full Text] [Related]
5. Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI.
Dirix P; Vandecaveye V; De Keyzer F; Stroobants S; Hermans R; Nuyts S
J Nucl Med; 2009 Jul; 50(7):1020-7. PubMed ID: 19525447
[TBL] [Abstract][Full Text] [Related]
6. Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology.
Loveless ME; Lawson D; Collins M; Nadella MV; Reimer C; Huszar D; Halliday J; Waterton JC; Gore JC; Yankeelov TE
Neoplasia; 2012 Jan; 14(1):54-64. PubMed ID: 22355274
[TBL] [Abstract][Full Text] [Related]
7. Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography.
Niermann KJ; Fleischer AC; Huamani J; Yankeelov TE; Kim DW; Wilson WD; Hallahan DE
J Ultrasound Med; 2007 Jun; 26(6):749-56. PubMed ID: 17526606
[TBL] [Abstract][Full Text] [Related]
8. Can combined 18F-FDG-PET and dynamic contrast-enhanced MRI predict behavior of desmoid tumors in patients with familial adenomatous polyposis?
Bhandari S; Taylor NJ; Sinha A; Sonoda L; Sanghera B; Wong WL; Goh V; Clark SK
Dis Colon Rectum; 2012 Oct; 55(10):1032-7. PubMed ID: 22965401
[TBL] [Abstract][Full Text] [Related]
9. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.
Jansen JF; Schöder H; Lee NY; Stambuk HE; Wang Y; Fury MG; Patel SG; Pfister DG; Shah JP; Koutcher JA; Shukla-Dave A
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):299-307. PubMed ID: 21236594
[TBL] [Abstract][Full Text] [Related]
10. 18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.
Oehler C; O'Donoghue JA; Russell J; Zanzonico P; Lorenzen S; Ling CC; Carlin S
J Nucl Med; 2011 Mar; 52(3):437-44. PubMed ID: 21321262
[TBL] [Abstract][Full Text] [Related]
11. Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity.
Messiou C; Orton M; Ang JE; Collins DJ; Morgan VA; Mears D; Castellano I; Papadatos-Pastos D; Brunetto A; Tunariu N; Mann H; Tessier J; Young H; Ghiorghiu D; Marley S; Kaye SB; deBono JS; Leach MO; deSouza NM
Radiology; 2012 Nov; 265(2):426-36. PubMed ID: 22891356
[TBL] [Abstract][Full Text] [Related]
12. Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.
Jiang Y; Allen D; Kersemans V; Devery AM; Bokobza SM; Smart S; Ryan AJ
Lung Cancer; 2015 Nov; 90(2):191-8. PubMed ID: 26323213
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.
Judson I; Scurr M; Gardner K; Barquin E; Marotti M; Collins B; Young H; Jürgensmeier JM; Leahy M
Clin Cancer Res; 2014 Jul; 20(13):3603-12. PubMed ID: 24714778
[TBL] [Abstract][Full Text] [Related]
14. Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.
Zhou LN; Wu N; Liang Y; Gao K; Li XY; Zhang LF
World J Surg Oncol; 2015 Mar; 13():111. PubMed ID: 25888731
[TBL] [Abstract][Full Text] [Related]
15. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
Kamoun WS; Ley CD; Farrar CT; Duyverman AM; Lahdenranta J; Lacorre DA; Batchelor TT; di Tomaso E; Duda DG; Munn LL; Fukumura D; Sorensen AG; Jain RK
J Clin Oncol; 2009 May; 27(15):2542-52. PubMed ID: 19332720
[TBL] [Abstract][Full Text] [Related]
16. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model.
Farrar CT; Kamoun WS; Ley CD; Kim YR; Catana C; Kwon SJ; Rosen BR; Jain RK; Sorensen AG
PLoS One; 2011 Mar; 6(3):e17228. PubMed ID: 21390238
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms.
Armbruster M; Zech CJ; Sourbron S; Ceelen F; Auernhammer CJ; Rist C; Haug A; Singnurkar A; Reiser MF; Sommer WH
J Magn Reson Imaging; 2014 Aug; 40(2):457-66. PubMed ID: 24347148
[TBL] [Abstract][Full Text] [Related]
19. Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors.
Goggi JL; Bejot R; Moonshi SS; Bhakoo KK
J Nucl Med; 2013 Sep; 54(9):1630-6. PubMed ID: 23907757
[TBL] [Abstract][Full Text] [Related]
20. Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma.
Lobo MR; Green SC; Schabel MC; Gillespie GY; Woltjer RL; Pike MM
Neuro Oncol; 2013 Dec; 15(12):1673-83. PubMed ID: 24092859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]